Aditxt (NASDAQ:ADTX) Shares Down 2.8% – Here’s What Happened

Aditxt, Inc. (NASDAQ:ADTX) shares fell 2.8% during trading on Friday . The company traded as low as $2.63 and last traded at $2.79. 69,141 shares changed hands during trading, a decline of 73% from the average session volume of 259,676 shares. The stock had previously closed at $2.87.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aditxt in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Aditxt has a consensus rating of “Sell”.

Aditxt Stock Down 2.8%

The firm has a market capitalization of $111,600.00, a P/E ratio of 0.00 and a beta of 1.41. The company’s 50 day moving average is $49.33 and its 200-day moving average is $113.37.

Institutional Trading of Aditxt

A hedge fund recently raised its stake in Aditxt stock. IFP Advisors Inc increased its position in shares of Aditxt, Inc. (NASDAQ:ADTX) by 66,926.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,054 shares of the company’s stock after buying an additional 10,039 shares during the quarter. IFP Advisors Inc owned about 17.64% of Aditxt worth $45,000 at the end of the most recent quarter. 15.54% of the stock is owned by hedge funds and other institutional investors.

Aditxt Company Profile

Aditxt, Inc, a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.